Daniel Kim to Melanoma
This is a "connection" page, showing publications Daniel Kim has written about Melanoma.
Connection Strength
4.593
-
Kim DY, Behbahani S, Moncayo A, Trepanowski N, Hartman RI. Disparities in melanoma presentation and overall survival among disaggregated Hispanic nationalities: A retrospective analysis of 2,517 patients in the National Cancer Database. Arch Dermatol Res. 2024 Jun 08; 316(7):377.
Score: 0.685
-
Kim DY, Dee EC, Cheng I, Hartman RI. Advanced melanoma presentation and disease-specific survival disparities among disaggregated Asian American, Native Hawaiian, and Pacific Islander populations. J Am Acad Dermatol. 2024 03; 90(3):623-626.
Score: 0.658
-
Kim DY, Swetter SM, Huhmann L, Dizon MP, Ferguson JM, Osborne TF, Spence AC, Ziad A, Fillmore N, Hartman RI. Real-world effectiveness of immune checkpoint inhibitors and BRAF/MEK inhibitors among veteran patients with cutaneous melanoma. J Am Acad Dermatol. 2024 03; 90(3):620-623.
Score: 0.658
-
Kim DY, Hartman RI. Incidence of In Situ and Invasive Cutaneous Melanomas During the COVID-19 Pandemic in the US. JAMA Dermatol. 2023 10 01; 159(10):1141-1145.
Score: 0.653
-
Kim DY, Marchetti MA, Hartman RI. Differences in thickness-specific incidence of cutaneous melanoma by county type in the United States, 2010 to 2019. J Am Acad Dermatol. 2023 09; 89(3):597-600.
Score: 0.637
-
Kim DY, Behbahani S, Hartman RI. Impact of COVID-19 pandemic on melanoma presentation by facility type and region in the United States. J Am Acad Dermatol. 2023 07; 89(1):175-178.
Score: 0.628
-
Moncayo AK, Ferguson JM, Dizon MP, Huhmann L, Kim DY, Do N, Brophy MT, Osborne TF, Spence AC, Fillmore NR, Swetter SM, Hartman RI. Area Deprivation Index and Melanoma Thickness in Veterans. JAMA Dermatol. 2025 Jun 01; 161(6):582-588.
Score: 0.183
-
Pan CX, Liu M, Lau CB, Lau WC, Kim DY, Saberi SA, Rowley R, Kanwar R, Giobbie-Hurder A, LeBoeuf NR, Nambudiri VE. Histopathological predictors of immune-related adverse events among patients with melanoma treated with immune checkpoint inhibitors. J Am Acad Dermatol. 2024 04; 90(4):826-829.
Score: 0.165
-
Pan CX, Kim DY, Lau CB, Lau WC, Rowley R, Kanwar R, LeBoeuf NR, Nambudiri VE. Comparative analysis of immune-related adverse events among patients with melanoma on immune checkpoint inhibitors: a retrospective cohort study. Br J Dermatol. 2023 10 25; 189(5):637-640.
Score: 0.164
-
Pan CX, Lau WC, Kim DY, Lau CB, Rowley R, Kanwar R, LeBoeuf NR, Nambudiri VE. Association between baseline lactate dehydrogenase and immune-related adverse events among patients with melanoma varies by tumor stage at immune checkpoint inhibitor initiation. J Am Acad Dermatol. 2023 12; 89(6):1264-1268.
Score: 0.162